Тargeted therapy for CF patients with F508del/F508del genotype
Authors:
- 1 July 2019
- journal article
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 29 (2) , 235-238
Abstract
Targeted therapy for cystic fibrosis (CF) is a novel approach to CF treatment that can restore and potentiate CFTR channel activity. Lumacaftor/ivacaftor combination therapy is related to significant clinical and functional benefits in CF patients who are homozygous for F508del CFTR mutation. The authors described a case of effective treatment with lumacaftor/ivacaftor combination in a homozygous F508del CF patient with severe lung disease. This experience demonstrates an urgent need to make this pathogenic treatment available for patients with this genotype in Russia.Keywords
This publication has 6 references indexed in Scilit:
- Pathogenic treatment of cystic fibrosis: the first clinical case in RussiaPULMONOLOGIYA, 2017
- CFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisFrontiers in Pharmacology, 2016
- Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysisThe Lancet Respiratory Medicine, 2016
- Progress in therapies for cystic fibrosisThe Lancet Respiratory Medicine, 2016
- Lumacaftor/Ivacaftor: A Review in Cystic FibrosisDrugs, 2016
- Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosisEuropean Respiratory Review, 2013